Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats

Abnish K. Gautam, Biju Bhargavan, Abdul M. Tyagi, Kamini Srivastava, Dinesh K. Yadav, Manmeet Kumar, Akanksha Singh, Jay S. Mishra, Amar Bahadur Singh, Sabyasachi Sanyal, Rakesh Maurya, Lakshmi Manickavasagam, Sheelendra P. Singh, Wahajuddin Wahajuddin, Girish K. Jain, Naibedya Chattopadhyay, Divya Singh

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Dietary soy isoflavones including genistein and daidzein have been shown to have favorable effects during estrogen deficiency in experimental animals and humans. We have evaluated osteogenic effect of cladrin and formononetin, two structurally related methoxydaidzeins found in soy food and other natural sources. Cladrin, at as low as 10 nM, maximally stimulated both osteoblast proliferation and differentiation by activating MEK-Erk pathway. On the other hand, formononetin maximally stimulated osteoblast differentiation at 100 nM that involved p38 MAPK pathway but had no effect on osteoblast proliferation. Unlike daidzein, these two compounds neither activated estrogen receptor in osteoblast nor had any effect on osteoclast differentiation. Daily oral administration of each of these compounds at 10.0 mg kg-1 day-1 dose to recently weaned female Sprague-Dawley rats for 30 consecutive days, increased bone mineral density at various anatomic positions studied. By dynamic histomorphometry of bone, we observed that rats treated with cladrin exhibited increased mineral apposition and bone formation rates compared with control, while formononetin had no effect. Cladrin had much better plasma bioavailability compared with formononetin. None of these compounds exhibited estrogen agonistic effect in uteri. Our data suggest that cladrin is more potent among the two in promoting parameters of peak bone mass achievement, which could be attributed to its stimulatory effect on osteoblast proliferation and better bioavailability. To the best of our knowledge, this is the first attempt to elucidate structure-activity relationship between the methoxylated forms of daidzein and their osteogenic effects.

Original languageEnglish (US)
Pages (from-to)318-327
Number of pages10
JournalJournal of Nutritional Biochemistry
Volume22
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Osteoblasts
Biological Availability
Rats
Bone
Bone and Bones
Minerals
Estrogens
Soy Foods
Isoflavones
Genistein
Mitogen-Activated Protein Kinase Kinases
p38 Mitogen-Activated Protein Kinases
Osteoclasts
Structure-Activity Relationship
Osteogenesis
Estrogen Receptors
Bone Density
Uterus
Oral Administration
Sprague Dawley Rats

Keywords

  • Differentiation
  • MAPK signaling
  • Osteogenic
  • Peak bone mass
  • Proliferation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats. / Gautam, Abnish K.; Bhargavan, Biju; Tyagi, Abdul M.; Srivastava, Kamini; Yadav, Dinesh K.; Kumar, Manmeet; Singh, Akanksha; Mishra, Jay S.; Singh, Amar Bahadur; Sanyal, Sabyasachi; Maurya, Rakesh; Manickavasagam, Lakshmi; Singh, Sheelendra P.; Wahajuddin, Wahajuddin; Jain, Girish K.; Chattopadhyay, Naibedya; Singh, Divya.

In: Journal of Nutritional Biochemistry, Vol. 22, No. 4, 04.2011, p. 318-327.

Research output: Contribution to journalArticle

Gautam, AK, Bhargavan, B, Tyagi, AM, Srivastava, K, Yadav, DK, Kumar, M, Singh, A, Mishra, JS, Singh, AB, Sanyal, S, Maurya, R, Manickavasagam, L, Singh, SP, Wahajuddin, W, Jain, GK, Chattopadhyay, N & Singh, D 2011, 'Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats', Journal of Nutritional Biochemistry, vol. 22, no. 4, pp. 318-327. https://doi.org/10.1016/j.jnutbio.2010.02.010
Gautam, Abnish K. ; Bhargavan, Biju ; Tyagi, Abdul M. ; Srivastava, Kamini ; Yadav, Dinesh K. ; Kumar, Manmeet ; Singh, Akanksha ; Mishra, Jay S. ; Singh, Amar Bahadur ; Sanyal, Sabyasachi ; Maurya, Rakesh ; Manickavasagam, Lakshmi ; Singh, Sheelendra P. ; Wahajuddin, Wahajuddin ; Jain, Girish K. ; Chattopadhyay, Naibedya ; Singh, Divya. / Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats. In: Journal of Nutritional Biochemistry. 2011 ; Vol. 22, No. 4. pp. 318-327.
@article{d88c1caeb2f24eba8e6cf96e24357f6a,
title = "Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats",
abstract = "Dietary soy isoflavones including genistein and daidzein have been shown to have favorable effects during estrogen deficiency in experimental animals and humans. We have evaluated osteogenic effect of cladrin and formononetin, two structurally related methoxydaidzeins found in soy food and other natural sources. Cladrin, at as low as 10 nM, maximally stimulated both osteoblast proliferation and differentiation by activating MEK-Erk pathway. On the other hand, formononetin maximally stimulated osteoblast differentiation at 100 nM that involved p38 MAPK pathway but had no effect on osteoblast proliferation. Unlike daidzein, these two compounds neither activated estrogen receptor in osteoblast nor had any effect on osteoclast differentiation. Daily oral administration of each of these compounds at 10.0 mg kg-1 day-1 dose to recently weaned female Sprague-Dawley rats for 30 consecutive days, increased bone mineral density at various anatomic positions studied. By dynamic histomorphometry of bone, we observed that rats treated with cladrin exhibited increased mineral apposition and bone formation rates compared with control, while formononetin had no effect. Cladrin had much better plasma bioavailability compared with formononetin. None of these compounds exhibited estrogen agonistic effect in uteri. Our data suggest that cladrin is more potent among the two in promoting parameters of peak bone mass achievement, which could be attributed to its stimulatory effect on osteoblast proliferation and better bioavailability. To the best of our knowledge, this is the first attempt to elucidate structure-activity relationship between the methoxylated forms of daidzein and their osteogenic effects.",
keywords = "Differentiation, MAPK signaling, Osteogenic, Peak bone mass, Proliferation",
author = "Gautam, {Abnish K.} and Biju Bhargavan and Tyagi, {Abdul M.} and Kamini Srivastava and Yadav, {Dinesh K.} and Manmeet Kumar and Akanksha Singh and Mishra, {Jay S.} and Singh, {Amar Bahadur} and Sabyasachi Sanyal and Rakesh Maurya and Lakshmi Manickavasagam and Singh, {Sheelendra P.} and Wahajuddin Wahajuddin and Jain, {Girish K.} and Naibedya Chattopadhyay and Divya Singh",
year = "2011",
month = "4",
doi = "10.1016/j.jnutbio.2010.02.010",
language = "English (US)",
volume = "22",
pages = "318--327",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats

AU - Gautam, Abnish K.

AU - Bhargavan, Biju

AU - Tyagi, Abdul M.

AU - Srivastava, Kamini

AU - Yadav, Dinesh K.

AU - Kumar, Manmeet

AU - Singh, Akanksha

AU - Mishra, Jay S.

AU - Singh, Amar Bahadur

AU - Sanyal, Sabyasachi

AU - Maurya, Rakesh

AU - Manickavasagam, Lakshmi

AU - Singh, Sheelendra P.

AU - Wahajuddin, Wahajuddin

AU - Jain, Girish K.

AU - Chattopadhyay, Naibedya

AU - Singh, Divya

PY - 2011/4

Y1 - 2011/4

N2 - Dietary soy isoflavones including genistein and daidzein have been shown to have favorable effects during estrogen deficiency in experimental animals and humans. We have evaluated osteogenic effect of cladrin and formononetin, two structurally related methoxydaidzeins found in soy food and other natural sources. Cladrin, at as low as 10 nM, maximally stimulated both osteoblast proliferation and differentiation by activating MEK-Erk pathway. On the other hand, formononetin maximally stimulated osteoblast differentiation at 100 nM that involved p38 MAPK pathway but had no effect on osteoblast proliferation. Unlike daidzein, these two compounds neither activated estrogen receptor in osteoblast nor had any effect on osteoclast differentiation. Daily oral administration of each of these compounds at 10.0 mg kg-1 day-1 dose to recently weaned female Sprague-Dawley rats for 30 consecutive days, increased bone mineral density at various anatomic positions studied. By dynamic histomorphometry of bone, we observed that rats treated with cladrin exhibited increased mineral apposition and bone formation rates compared with control, while formononetin had no effect. Cladrin had much better plasma bioavailability compared with formononetin. None of these compounds exhibited estrogen agonistic effect in uteri. Our data suggest that cladrin is more potent among the two in promoting parameters of peak bone mass achievement, which could be attributed to its stimulatory effect on osteoblast proliferation and better bioavailability. To the best of our knowledge, this is the first attempt to elucidate structure-activity relationship between the methoxylated forms of daidzein and their osteogenic effects.

AB - Dietary soy isoflavones including genistein and daidzein have been shown to have favorable effects during estrogen deficiency in experimental animals and humans. We have evaluated osteogenic effect of cladrin and formononetin, two structurally related methoxydaidzeins found in soy food and other natural sources. Cladrin, at as low as 10 nM, maximally stimulated both osteoblast proliferation and differentiation by activating MEK-Erk pathway. On the other hand, formononetin maximally stimulated osteoblast differentiation at 100 nM that involved p38 MAPK pathway but had no effect on osteoblast proliferation. Unlike daidzein, these two compounds neither activated estrogen receptor in osteoblast nor had any effect on osteoclast differentiation. Daily oral administration of each of these compounds at 10.0 mg kg-1 day-1 dose to recently weaned female Sprague-Dawley rats for 30 consecutive days, increased bone mineral density at various anatomic positions studied. By dynamic histomorphometry of bone, we observed that rats treated with cladrin exhibited increased mineral apposition and bone formation rates compared with control, while formononetin had no effect. Cladrin had much better plasma bioavailability compared with formononetin. None of these compounds exhibited estrogen agonistic effect in uteri. Our data suggest that cladrin is more potent among the two in promoting parameters of peak bone mass achievement, which could be attributed to its stimulatory effect on osteoblast proliferation and better bioavailability. To the best of our knowledge, this is the first attempt to elucidate structure-activity relationship between the methoxylated forms of daidzein and their osteogenic effects.

KW - Differentiation

KW - MAPK signaling

KW - Osteogenic

KW - Peak bone mass

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=78651239360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651239360&partnerID=8YFLogxK

U2 - 10.1016/j.jnutbio.2010.02.010

DO - 10.1016/j.jnutbio.2010.02.010

M3 - Article

C2 - 20579866

AN - SCOPUS:78651239360

VL - 22

SP - 318

EP - 327

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 4

ER -